BR112019014209A2 - Sistema de liberação de fármaco, método para provimento do mesmo, partículas semelhantes a vírus (vlp), composição e uso do sistema de liberação de fármaco - Google Patents

Sistema de liberação de fármaco, método para provimento do mesmo, partículas semelhantes a vírus (vlp), composição e uso do sistema de liberação de fármaco Download PDF

Info

Publication number
BR112019014209A2
BR112019014209A2 BR112019014209-6A BR112019014209A BR112019014209A2 BR 112019014209 A2 BR112019014209 A2 BR 112019014209A2 BR 112019014209 A BR112019014209 A BR 112019014209A BR 112019014209 A2 BR112019014209 A2 BR 112019014209A2
Authority
BR
Brazil
Prior art keywords
vlps
vlp
composition
pentamers
delivery system
Prior art date
Application number
BR112019014209-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Victoria Demina
Heiko Manninga
Sergey Sotnikov
Marcus STAPF
Katja Janina KOßMANN
Original Assignee
Neuway Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuway Pharma Gmbh filed Critical Neuway Pharma Gmbh
Publication of BR112019014209A2 publication Critical patent/BR112019014209A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112019014209-6A 2018-12-18 2018-12-18 Sistema de liberação de fármaco, método para provimento do mesmo, partículas semelhantes a vírus (vlp), composição e uso do sistema de liberação de fármaco BR112019014209A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/085699 WO2020125962A1 (en) 2018-12-18 2018-12-18 A novel drug delivery system and methods providing thereof

Publications (1)

Publication Number Publication Date
BR112019014209A2 true BR112019014209A2 (pt) 2021-09-28

Family

ID=65009711

Family Applications (3)

Application Number Title Priority Date Filing Date
BR112019014209-6A BR112019014209A2 (pt) 2018-12-18 2018-12-18 Sistema de liberação de fármaco, método para provimento do mesmo, partículas semelhantes a vírus (vlp), composição e uso do sistema de liberação de fármaco
BR112021010758-4A BR112021010758A2 (pt) 2018-12-18 2019-10-14 Método para fornecer uma vlp derivada de vírus john cunningham
BR102019026837-9A BR102019026837A2 (pt) 2018-12-18 2019-12-16 vlp para o tratamento de uma doença de depósito lisossômico

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR112021010758-4A BR112021010758A2 (pt) 2018-12-18 2019-10-14 Método para fornecer uma vlp derivada de vírus john cunningham
BR102019026837-9A BR102019026837A2 (pt) 2018-12-18 2019-12-16 vlp para o tratamento de uma doença de depósito lisossômico

Country Status (12)

Country Link
US (4) US11279938B2 (cg-RX-API-DMAC7.html)
EP (2) EP3688147B8 (cg-RX-API-DMAC7.html)
JP (3) JP6884432B2 (cg-RX-API-DMAC7.html)
CN (3) CN111587289B (cg-RX-API-DMAC7.html)
BR (3) BR112019014209A2 (cg-RX-API-DMAC7.html)
CA (3) CA3049197C (cg-RX-API-DMAC7.html)
DK (1) DK3688147T3 (cg-RX-API-DMAC7.html)
ES (1) ES2933275T3 (cg-RX-API-DMAC7.html)
HU (1) HUE060952T2 (cg-RX-API-DMAC7.html)
PL (1) PL3688147T3 (cg-RX-API-DMAC7.html)
SI (1) SI3688147T1 (cg-RX-API-DMAC7.html)
WO (4) WO2020125962A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526528A (ja) * 2020-05-22 2023-06-21 ノイウェイ ファルマ ゲーエムベーハー 白質ジストロフィーの処置のためのvlp
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN115448980A (zh) * 2021-06-08 2022-12-09 戴德森医疗财团法人嘉义基督教医院 表面链结标靶多肽的类病毒颗粒及其用途
EP4166672A1 (en) 2021-10-15 2023-04-19 NEUWAY Pharma GmbH A novel method for purification of protein- or peptide-based capsules
CN116554279A (zh) * 2022-01-28 2023-08-08 思凯生科有限公司 包含有专一性表达于前列腺细胞的表达质粒的类病毒颗粒及其用途
WO2024079361A1 (en) 2022-10-14 2024-04-18 Neuway Pharma Gmbh A PROTEIN- OR PEPTIDE-BASED CAPSULE (PPC), PREFERABLY A VLP, LOADED WITH A MESSENGER RNA (mRNA) AND A METHOD OF PRODUCTION AND PURIFICATION THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
FR2920158B1 (fr) 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
SG11201609314XA (en) * 2014-05-14 2016-12-29 Esteve Labor Dr Adenoassociated virus vectors for the treatment of lysosomal storage disorders

Also Published As

Publication number Publication date
CN111587289A (zh) 2020-08-25
EP3688147A1 (en) 2020-08-05
US20230159938A1 (en) 2023-05-25
PL3688147T3 (pl) 2023-01-09
JP2022551531A (ja) 2022-12-09
WO2021074123A1 (en) 2021-04-22
CN111333702A (zh) 2020-06-26
EP3688147B1 (en) 2022-09-14
JP6884432B2 (ja) 2021-06-09
SI3688147T1 (sl) 2023-03-31
WO2020125962A1 (en) 2020-06-25
JP2020105169A (ja) 2020-07-09
JP2021502951A (ja) 2021-02-04
WO2020126116A1 (en) 2020-06-25
CA3065548A1 (en) 2020-06-18
WO2020126151A1 (en) 2020-06-25
US20230157972A1 (en) 2023-05-25
HUE060952T2 (hu) 2023-05-28
CA3121689A1 (en) 2020-06-25
EP3688147B8 (en) 2022-10-26
CN111587289B (zh) 2024-04-12
CA3049197C (en) 2023-01-03
US20210301302A1 (en) 2021-09-30
ES2933275T3 (es) 2023-02-03
EP4045638A1 (en) 2022-08-24
US11279938B2 (en) 2022-03-22
CN115135757A (zh) 2022-09-30
CA3049197A1 (en) 2020-05-18
US20200224205A1 (en) 2020-07-16
DK3688147T3 (da) 2022-12-19
BR102019026837A2 (pt) 2020-10-27
BR112021010758A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
ES2933275T3 (es) Un sistema de suministro de fármacos novedoso y métodos para proporcionar los mismos
JP2019525901A (ja) 脂質ナノ粒子の安定化製剤
JP2016531149A (ja) カプセル化細胞療法カートリッジ
US20230310652A1 (en) Vlp for the treatment of leukodystrophies
EP3670652A1 (en) Vlp for the treatment of a lysosomal storage disease
HK40035156A (en) A novel drug delivery system and methods providing thereof
HK40035156B (en) A novel drug delivery system and methods providing thereof
WO2024153767A1 (en) Pharmaceutical formulations of gene delivery vehicles
EP4166672A1 (en) A novel method for purification of protein- or peptide-based capsules
EP4651883A1 (en) Pharmaceutical formulations of gene delivery vehicles
WO2024079361A1 (en) A PROTEIN- OR PEPTIDE-BASED CAPSULE (PPC), PREFERABLY A VLP, LOADED WITH A MESSENGER RNA (mRNA) AND A METHOD OF PRODUCTION AND PURIFICATION THEREOF
HK1208046A1 (en) A novel drug delivery system based on jcv-vlp

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements